Akif Selim Yavuz

6PUBLICATIONS
62CO-AUTHORS
Gene and molecular therapyHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 27, 2026
Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia.

|Dec 02, 2022
Circulating CD133+/–CD34– Have Increased c-MYC Expression in Myeloproliferative Neoplasms

İldeniz Uslu Bıçak, Berkay Tokcan, Akif Selim Yavuz

|Oct 19, 2022
OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment.

Betul Bozkurt Bulakcı, Aynur Daglar Aday, Basak Gurtekin

|Oct 03, 2020
Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.

Hans Hägglund, Akif Selim Yavuz, Arta Dreimane

|Sep 12, 2020
The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms.

Aynur Daglar-Aday, Basak Akadam-Teker, Ipek Yonal-Hindilerden

|Feb 29, 2020
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.

Jakub Trizuljak, Wolfgang R Sperr, Lucie Nekvindová

Pageof 1

Frequent Collaborators

2 joint publications

Aynur Daglar-Aday

1 joint publications

Jakub Trizuljak

1 joint publications

Wolfgang R Sperr

1 joint publications

Lucie Nekvindová